Multiple myeloma trials in China

In China 203 Also abroad 703

203 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

No phaseTaking people
Novel CD19/BCMA Dual-Targeted CAR-T Cell Therapy for the Treatment of Relapsed/Refractory Multiple Myeloma
Where
Hangzhou
Age
18 years to 75 years
People
25
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07359014
No phaseNot yet taking people in China
Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma
Where
Beijing
Age
18 years to 85 years
People
30
Run by
Peking Union Medical College Hospital
See details and how to joinNCT07353554
Phase 4Not yet taking people in China
Isa-VRD in TIE HRMM
Where
Beijing
Age
18 years to 80 years
People
117
Run by
Peking Union Medical College Hospital
See details and how to joinNCT07334535
Early phase 1Taking people
JY232(JY232) Injection in Relapsed/Refractory Multiple Myeloma
Where
Foshan
Age
18 years to 75 years
People
9
Run by
Shenzhen Genocury Biotech Co., Ltd.
See details and how to joinNCT07336823
No phaseNot yet taking people in China
ASPIRE: A Registry Study Of Chinese Patients With TCE-RRMM Treated By Elranatamab
Where
Beijing
Age
18 years and over
People
159
Run by
Peking University People's Hospital
See details and how to joinNCT07320326
Phase 4Taking people
Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma
Where
Hangzhou
Age
18 years to 80 years
People
100
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT05722405
Phase 2Taking people
A Study of F182112 in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Where
Tianjin
Age
18 years and over
People
90
Run by
Shandong New Time Pharmaceutical Co., LTD
See details and how to joinNCT07312188
No phaseTaking people
LCAR-F33S in Treatment of Relapsed/Refractory Multiple Myeloma
Where
Beijing, Tianjin, Wuhan
Age
18 years and over
People
35
Run by
Nanjing Legend Biotech Co.
See details and how to joinNCT07100067
No phaseTaking people
Randomised Controlled Trial of Artificial Intelligence-assisted Health Education
Where
Wuhan
Age
18 years to 90 years
People
196
Run by
Zhongnan Hospital
See details and how to joinNCT07305337
No phaseTaking people
Real-world Immuno-therapy in Chinese Newly Diagnosed Multiple Myeloma Patients
Where
Beijing
Age
18 years and over
People
500
Run by
Peking University People's Hospital
See details and how to joinNCT07296627
Early phase 1Taking people
A Clinical Study to Evaluate LVIVO-TaVec200 for the Treatment of Relapsed/Refractory Multiple Myeloma
Where
Nanjing, Shanghai, Xi'an, Xuzhou, Zhengzhou
Age
18 years and over
People
36
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT07294625
Phase 1Taking people
A Clinical Study Assessing the Subcutaneous Formulation of TQB2934 for Injection in Subjects With Malignant Plasma Cell Tumors
Where
Chengde, Chongqing, Guangzhou, Heze, Nanchang, Nanchong, Nanjing, Shanghai, Suzhou, Tangshan, Tianjin, Xi’an
Age
18 years to 75 years
People
42
Run by
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
See details and how to joinNCT07179679
No phaseTaking people
Universal CAR-T Cell Therapy for MM
Where
Shanghai
Age
18 years and over
People
6
Run by
Bioray Laboratories
See details and how to joinNCT07248176
Phase 1Taking people
Dual-target BCMA-CD19 CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Where
Shanghai
Age
18 years to 75 years
People
18
Run by
Beijing GoBroad Hospital
See details and how to joinNCT07003555
Phase 1Taking people
Dual-target BCMA-GPRC5D CAR-T Cell Therapy for RR/MM With Extramedullary Infiltration
Where
Shanghai
Age
18 years to 75 years
People
18
Run by
Beijing GoBroad Hospital
See details and how to joinNCT07003568
Phase 1Taking people
Allogeneic UCB-derived, Dual-targeting BCMA/CD19 CAR-T for Relapsed/Refractory Multiple Myeloma
Where
Xi'an
Age
18 years to 75 years
People
18
Run by
Xi'an No.3 Hospital
See details and how to joinNCT07139509
Early phase 1Taking people
CAR19-BCMA Dual-target CAR-T in the Treatment of Relapsed / Refractory Multiple Myeloma
Where
Tianjin
Age
18 years to 70 years
People
9
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07249073
No phaseTaking people
High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)
Where
Xining
People
1,000
Run by
Yigeng Cao,MD,PhD
See details and how to joinNCT07205523
Early phase 1Taking people
A Study of CT0596 in Relapsed/Refractory Multiple Myeloma and Relapsed/ Refractory Plasma Cell Leukemia
Where
Suzhou
Age
18 years and over
People
24
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT06730256
Phase 3Not yet taking people in China
Study of CM336 in Relapsed or Refractory Multiple Myeloma Patients
Where
Tianjin
Age
18 years and over
People
280
Run by
Keymed Biosciences Co.Ltd
See details and how to joinNCT07181239
Phase 1Taking people
BCMA-CD19 cCAR in Multiple Myeloma and Plasmacytoid Lymphoma
Where
Chengdu, Shenzhen
People
12
Run by
iCell Gene Therapeutics
See details and how to joinNCT04162353
No phaseNot yet taking people in China
Risk-adapted Therapeutic Strategy in +1q NDMM
Where
Changchun
People
200
Run by
FengYan Jin
See details and how to joinNCT07045168
No phaseTaking people
A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma
Where
Changzhou, Nanjing, Nantong, Taizhou, Yancheng
Age
65 years and over
People
112
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT06497738
Phase 1/2Taking people
Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
Where
Beijing, Guangzhou, Hangzhou
Age
18 years and over
People
84
Run by
Zhejiang ACEA Pharmaceutical Co. Ltd.
See details and how to joinNCT05565807
No phaseTaking people
Aponermin-Based Bridging Therapy Prior to CAR-T Infusion in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease
Where
Beijing, Tianjin
Age
18 years and over
People
20
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06793475